Acumen Hypotension Prediction Index – EV1000 Clinical Platform vs Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel)

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
Acumen Hypotension Prediction Index – EV1000 Clinical Platform
by Edwards Lifesciences
VS
Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel)
by Element Science

AI Verdict

Tool A is designed for real-time prediction and management of hypotension in acute care settings, providing clinicians with advanced hemodynamic insights. In contrast, Tool B is a wearable device focused on continuous monitoring, detection, and treatment of life-threatening arrhythmias for patients outside of acute care. While both leverage AI in cardiology, their distinct applications in predicting hemodynamic instability versus actively treating cardiac rhythm disorders make them suitable for different clinical needs.

Choose Acumen Hypotension Prediction Index – EV1000 Clinical Platform if…

Choose Acumen Hypotension Prediction Index if you require real-time, predictive analytics to proactively manage and prevent hypotensive events in critically ill or surgical patients. This tool is ideal for anesthesiologists and critical care teams needing advanced hemodynamic insights to optimize patient stability and reduce intraoperative or ICU hypotension.

View Acumen Hypotension Prediction Index – EV1000 Clinical Platform →

Choose Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel) if…

Choose Jewel Patch Wearable Cardioverter Defibrillator if your patient requires continuous, long-term monitoring and potential treatment for life-threatening arrhythmias outside of an acute care setting. Its discreet, water-resistant design and high patient compliance make it suitable for individuals needing ongoing cardiac protection in their daily lives.

View Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel) →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Acumen Hypotension Prediction Index – EV1000 Clinical Platform Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel)
Deployment On-premise (integrated with EV1000 clinical platform and HemoSphere advanced monitoring platform) Wearable device with mobile app
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel)

Tool B, the Jewel Patch Wearable Cardioverter Defibrillator, is designed for high patient compliance with its discreet, water-resistant, patch-based form factor, allowing for continuous wear including showering. This focus on patient-centric design for daily living makes it highly usable for its intended users outside of a clinical setting. Tool A is integrated into a clinical platform, focusing on clinician usability within a hospital environment.

Clinical Value

Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel)

While Tool A offers significant value by predicting hypotension up to 15 minutes in advance and providing insights for proactive management, Tool B directly detects and treats life-threatening arrhythmias. The immediate, life-saving therapeutic intervention provided by the Jewel P-WCD for sudden cardiac arrest offers a direct and critical clinical outcome.

Pricing & Value

Tie

Both Tool A and Tool B explicitly state 'contact-for-pricing' or 'contact vendor' and that pricing details are 'not publicly available'. Without any transparent pricing information for either product, it is impossible to conduct a meaningful comparison of their value propositions.

Enterprise Readiness

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Tool A, the Acumen HPI, is integrated with the Edwards Lifesciences HemoSphere Advanced Monitoring Platform, indicating it is built for seamless integration into existing hospital infrastructure and workflows. Edwards Lifesciences is a well-established medical device company, suggesting robust enterprise-level deployment and support. Tool B, while having a modern cloud and app architecture, is from a newer company and targets remote monitoring, which presents different integration challenges.

Innovation

Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel)

Both tools leverage machine learning, but Tool B's innovation in combining a discreet, water-resistant, patch-based wearable device with the capability to detect and *treat* life-threatening arrhythmias is particularly groundbreaking. This form factor for a cardioverter defibrillator significantly enhances patient comfort and compliance for a critical therapeutic device.

Support & Docs

Acumen Hypotension Prediction Index – EV1000 Clinical Platform

Edwards Lifesciences (Tool A) offers comprehensive support, including 24/7 technical support, a dedicated patient support center, and extensive clinical education resources with a learning portal. While Element Science (Tool B) provides detailed manuals and instructional videos, and emphasizes patient training, the breadth and scale of support from a large, established company like Edwards Lifesciences for its integrated clinical platform appear more robust.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Acumen Hypotension Prediction Index – EV1000 Clinical Platform Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel)
Name Acumen Hypotension Prediction Index u2013 EV1000 Clinical Platform Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel)
Company Edwards Lifesciences Element Science, Inc.
Description The Acumen Hypotension Prediction Index (HPI) software by Edwards Lifesciences uses machine learning to predict hypotensive events up to 15 minutes in advance, providing clinicians with insights into hemodynamic instability and potential causes to help reduce intraoperative hypotension. The Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) is a water-resistant, patch-based device with a machine learning algorithm for continuous heart monitoring and treatment of life-threatening arrhythmias, designed for high patient compliance.
Tagline Predicting and managing hypotension before it occurs. Designed to be worn. Designed to save lives.
Categories Cardiology AI, Surgical AI, Triage & ER/ICU AI Cardiology AI, Wearables & Remote Monitoring (RPM)
Specialties Anesthesiology, Critical Care, Emergency Medicine Cardiology

Videos

Demos, reviews, and walkthroughs featuring Acumen Hypotension Prediction Index – EV1000 Clinical Platform and Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel).

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Tool A, Acumen HPI, is designed for acute care settings such as the OR, ICU, and ER, integrating with Edwards Lifesciences monitoring platforms to provide real-time hemodynamic insights and predict hypotension up to 15 minutes in advance. Tool B, Jewel P-WCD, is an ambulatory wearable device for continuous heart monitoring and treatment of life-threatening arrhythmias, with data accessible via an associated mobile app and cloud platform for remote oversight.
Tool A integrates with the Edwards Lifesciences HemoSphere Advanced Monitoring Platform, and while studies mention automated extraction of device-captured data for research, direct EHR integration for routine clinical data flow is not explicitly detailed. Tool B provides near real-time therapy information to the medical team via its associated mobile app and cloud platform, but the extent of direct integration with hospital EHR systems is not specified in the provided information.
Tool A's machine learning algorithm predicts hypotension up to 10 minutes in advance with a specificity of 89%, a sensitivity of 90%, and an AUC of 0.95. Tool B's machine learning algorithm for arrhythmia detection has demonstrated a very low inappropriate shock rate of 0.36 shocks per 100 patient-months and successfully converted eight separate ventricular tachycardia or ventricular fibrillation events in six patients.
For Tool A, using the HPI software requires training and education to interpret the HPI parameter, Smart Alerts, and the Smart Trend and Relationship View screens. For Tool B, the focus for clinicians would be on monitoring data from the associated mobile app and cloud platform, with the device itself designed for high patient compliance. Specific time-to-value estimates for clinical benefits are not detailed for either tool in the provided information.
For Tool A, multi-site deployment would involve integrating with existing or new Edwards Lifesciences HemoSphere Advanced Monitoring Platforms and dedicated sensors across each site, and ensuring staff training on HPI use. For Tool B, deployment involves distributing the patch-based devices and managing data flow through its associated mobile application and cloud platform across multiple locations. The specific challenges for multi-site data management and training are not explicitly detailed beyond the need for training for Tool A.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Acumen Hypotension Prediction Index – EV1000 Clinical Platform or Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) (Jewel)

AI Tool Finder
AI-powered search. Results may not be comprehensive.